AMPH Relative Valuation
AMPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AMPH is overvalued; if below, it's undervalued.
Historical Valuation
Amphastar Pharmaceuticals Inc (AMPH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 8.09 is considered Undervalued compared with the five-year average of 14.37. The fair price of Amphastar Pharmaceuticals Inc (AMPH) is between 33.21 to 58.13 according to relative valuation methord. Compared to the current price of 27.66 USD , Amphastar Pharmaceuticals Inc is Undervalued By 16.73%.
Relative Value
Fair Zone
33.21-58.13
Current Price：27.66
16.73%
Undervalued
7.97
PE
1Y
3Y
5Y
Trailing
Forward
6.21
EV/EBITDA
Amphastar Pharmaceuticals Inc. (AMPH) has a current EV/EBITDA of 6.21. The 5-year average EV/EBITDA is 8.57. The thresholds are as follows: Strongly Undervalued below 5.01, Undervalued between 5.01 and 6.79, Fairly Valued between 10.35 and 6.79, Overvalued between 10.35 and 12.13, and Strongly Overvalued above 12.13. The current Forward EV/EBITDA of 6.21 falls within the Undervalued range.
7.97
EV/EBIT
Amphastar Pharmaceuticals Inc. (AMPH) has a current EV/EBIT of 7.97. The 5-year average EV/EBIT is 10.55. The thresholds are as follows: Strongly Undervalued below 5.46, Undervalued between 5.46 and 8.00, Fairly Valued between 13.09 and 8.00, Overvalued between 13.09 and 15.64, and Strongly Overvalued above 15.64. The current Forward EV/EBIT of 7.97 falls within the Undervalued range.
1.75
PS
Amphastar Pharmaceuticals Inc. (AMPH) has a current PS of 1.75. The 5-year average PS is 2.56. The thresholds are as follows: Strongly Undervalued below 1.30, Undervalued between 1.30 and 1.93, Fairly Valued between 3.20 and 1.93, Overvalued between 3.20 and 3.83, and Strongly Overvalued above 3.83. The current Forward PS of 1.75 falls within the Undervalued range.
6.00
P/OCF
Amphastar Pharmaceuticals Inc. (AMPH) has a current P/OCF of 6.00. The 5-year average P/OCF is 9.83. The thresholds are as follows: Strongly Undervalued below 4.76, Undervalued between 4.76 and 7.29, Fairly Valued between 12.37 and 7.29, Overvalued between 12.37 and 14.91, and Strongly Overvalued above 14.91. The current Forward P/OCF of 6.00 falls within the Undervalued range.
8.10
P/FCF
Amphastar Pharmaceuticals Inc. (AMPH) has a current P/FCF of 8.10. The 5-year average P/FCF is 9.63. The thresholds are as follows: Strongly Undervalued below -104.66, Undervalued between -104.66 and -47.52, Fairly Valued between 66.77 and -47.52, Overvalued between 66.77 and 123.92, and Strongly Overvalued above 123.92. The current Forward P/FCF of 8.10 falls within the Historic Trend Line -Fairly Valued range.
Amphastar Pharmaceuticals Inc (AMPH) has a current Price-to-Book (P/B) ratio of 1.65. Compared to its 3-year average P/B ratio of 2.99 , the current P/B ratio is approximately -44.95% higher. Relative to its 5-year average P/B ratio of 2.86, the current P/B ratio is about -42.52% higher. Amphastar Pharmaceuticals Inc (AMPH) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 7.35%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 6.33% , the current FCF yield is about -100.00% lower.
1.62
P/B
Median3y
2.99
Median5y
2.86
8.94
FCF Yield
Median3y
7.35
Median5y
6.33
Competitors Valuation Multiple
The average P/S ratio for AMPH's competitors is 0.00, providing a benchmark for relative valuation. Amphastar Pharmaceuticals Inc Corp (AMPH) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 0.33%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AMPH decreased by 26.88% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 9.20 to 11.96.
The secondary factor is the Revenue Growth, contributed 0.33%to the performance.
Overall, the performance of AMPH in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Amphastar Pharmaceuticals Inc (AMPH) currently overvalued or undervalued?
What is Amphastar Pharmaceuticals Inc (AMPH) fair value?
How does AMPH's valuation metrics compare to the industry average?
What is the current P/B ratio for Amphastar Pharmaceuticals Inc (AMPH) as of Dec 05 2025?
What is the current FCF Yield for Amphastar Pharmaceuticals Inc (AMPH) as of Dec 05 2025?
What is the current Forward P/E ratio for Amphastar Pharmaceuticals Inc (AMPH) as of Dec 05 2025?